Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

  • Srdan Verstovsek
    Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX;
  • Francesco Passamonti
    Department of Medicine and Surgery, University of Insubria, Varese, Italy;
  • Alessandro Rambaldi
    Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXII, Bergamo, Italy;
  • Giovanni Barosi
    Center for the Study of Myelofibrosis, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo Foundation, Pavia, Italy;
  • Elisa Rumi
    Department of Molecular Medicine, University of Pavia, Pavia, Italy;
  • Elisabetta Gattoni
    Department of Oncology, Ospedale Santo Spirito, Casale Monferrato, Italy;
  • Lisa Pieri
    Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, Florence, Italy;
  • Huiling Zhen
    Incyte Corporation, Wilmington, DE; and
  • Muriel Granier
    Incyte Corporation, Wilmington, DE; and
  • Albert Assad
    Incyte Corporation, Wilmington, DE; and
  • Mario Cazzola
    Department of Molecular Medicine, University of Pavia, Pavia, Italy;
  • Hagop M. Kantarjian
    Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX;
  • Tiziano Barbui
    Clinical Research Foundation (FROM), Ospedale Papa Giovanni XXIII, Bergamo, Italy
  • Alessandro M. Vannucchi
    Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, Florence, Italy;

収録刊行物

  • Blood

    Blood 130 (15), 1768-1771, 2017-10-12

    American Society of Hematology

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ